Pharmaceutical supply chains are undergoing rapid automation upgrades to overcome persistent bottlenecks in GLP-1 receptor agonist manufacturing.
Sterile Fill-Finish Capacity
The bottleneck has moved from active pharmaceutical ingredient (API) synthesis to high-speed sterile filling lines. Device assembly plants are investing over $3 billion globally to automate auto-injector pen assembly.
Supply Chain Outlook
Contract Development and Manufacturing Organizations (CDMOs) project that full capacity stabilization will not be achieved until late 2025, keeping retail distribution tightly allocated.